Current perspectives for AT1-receptor blockers in the management of heart failure

Swedberg, Karl

doi:10.1038/sj.jhh.1001439

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plus, due to the existence of alternative pathways for the formation of angiotensin II, ACE inhibitors rarely rescue patient from a long-term perspective. Together, they made optimization of this pharmacotherapeutic strategy necessary ( 17 ). From this end, AT-1 receptor blocker (ARB) such as losartan came into being.…”

Section: The Rationale Of Drug Therapy In Heart Failurementioning

confidence: 99%

Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

Zhou,

Liu,

Huang

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure, a prevailing global health issue, imposes a substantial burden on both healthcare systems and patients worldwide. With an escalating prevalence of heart failure, prolonged survival rates, and an aging demographic, an increasing number of individuals are progressing to more advanced phases of this incapacitating ailment. Against this backdrop, the quest for pharmacological agents capable of addressing the diverse subtypes of heart failure becomes a paramount pursuit. From this viewpoint, the present article focuses on Omecamtiv Mecarbil (OM), an emerging chemical compound said to exert inotropic effects without altering calcium homeostasis. For the first time, as a review, the present article uniquely started from the very basic pathophysiology of heart failure, its classification, and the strategies underpinning drug design, to on-going debates of OM's underlying mechanism of action and the latest large-scale clinical trials. Furthermore, we not only saw the advantages of OM, but also exhaustively summarized the concerns in sense of its effects. These of no doubt make the present article the most systemic and informative one among the existing literature. Overall, by offering new mechanistic insights and therapeutic possibilities, OM has carved a significant niche in the treatment of heart failure, making it a compelling subject of study.

show abstract

Section: The Rationale Of Drug Therapy In Heart Failurementioning

confidence: 99%

Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

Zhou,

Liu,

Huang

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…9 Treatment options in 'diastolic heart failure' are also not well defined by anything other than a few therapeutic clinical trials, many of which are hampered by the clinical definition of patients but do show evident morbidity and mortality. 10 …”

Section: Disease Definition In Individual Patients and Prognosismentioning

confidence: 99%

How far can population epidemiology contribute to defining the relationship between hypertension and left ventricular systolic dysfunction?

2005

View full text Add to dashboard Cite

“…ARBs and ACE inhibitors have demonstrated important advantages in treating systolic heart failure, 26–33 though the optimal doses have not been fully clarified for either class. Efforts to explore monotherapies or combination therapies at high doses may provide new insight.…”

Section: Clinical Trials In Systolic Heart Failurementioning

confidence: 99%

Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction

Weir

2004

J of Clinical Hypertension

View full text Add to dashboard Cite

Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II receptor blocker to existing antihypertensive regimens reduces cardiovascular and renal risk, which may, in part, be a result of blocking the effects of angiotensin II. Though the antihypertensive dose response of these agents is well documented, the dose response for optimal target organ protection has not yet been clarified. A review of recent studies of angiotensin II receptor blockers in hypertension, acute myocardial infarction, heart failure, and nephropathy provide some data on specific drugs, doses, and risk reduction. Taken as a whole, these studies suggest the highest doses tested, which are at the upper limit of the antihypertensive range, provide greater risk reduction than lower doses. What is unknown is whether even higher doses or full-dose angiotensin II receptor blockers plus full-dose angiotensin-converting enzyme inhibitors might provide even greater risk reduction. Data from ongoing trials will provide additional insight.

show abstract

Current perspectives for AT1-receptor blockers in the management of heart failure

Cited by 3 publications

References 21 publications

Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

How far can population epidemiology contribute to defining the relationship between hypertension and left ventricular systolic dysfunction?

Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction

Contact Info

Product

Resources

About